Phosphodiesterase inhibitors may be indicated in the treatment of postulated vasoactive neuropeptide autoimmune fatigue-related disorders.
Staines
Donald R
DR
D001327:Autoimmune Diseases / Q000188:drug therapy*; D000242:Cyclic AMP / Q000378:metabolism; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy*; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D009479:Neuropeptides / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D020889:Rolipram / Q000627:therapeutic use*
D009479:Neuropeptides; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D020889:Rolipram; D007099:Imipramine